Related Experiment Videos
[Exercise testing of the chronic effects of bunazosin hydrochloride on dilated cardiomyopathy]
Insights
Bunazosin hydrochloride improved exercise tolerance in patients with dilated cardiomyopathy (DCM). This cardiac medication enhanced physical function without altering resting hemodynamics.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Dilated cardiomyopathy (DCM) is a serious cardiac condition.
- Current treatments aim to improve cardiac function and patient outcomes.
Purpose:
- To evaluate the effects of bunazosin hydrochloride on patients with DCM.
- To assess changes in hemodynamics, cardiac function, and exercise tolerance.
Summary:
- Bunazosin hydrochloride (3-mg oral dose) was given to 10 DCM patients (NYHA class II).
- Measurements included hemodynamics, chest X-ray, echocardiography, humoral factors, and exercise tolerance over 8 weeks.
- Aldosterone levels decreased significantly, while symptom-limited exercise duration increased. Heart rate and blood pressure also reduced during exercise.
Impact:
- Bunazosin appears to improve cardiac function and exercise tolerance in DCM patients.
- The medication shows efficacy at doses that do not compromise resting hemodynamics.
Abstract:
Bunazosin hydrochloride was administrated in 3-mg oral doses to the 10 patients (6 males and 4 females, average 49.9 years) with dilated cardiomyopathy (DCM) of class II in the NYHA functional classification. Then we observed the changes in their hemodynamics at rest, chest X-ray, echocardiography, humoral factors and symptom-limited exercise tolerance with treadmill testing before treatment and 4 and 8 weeks after administration. All but the left ventricular end-diastolic diameter after 8 weeks were unchanged. Of the humoral factors, only aldosterone decreased significantly during the treatment. On the other hand, the duration of symptom-limited exercise was prolonged significantly, and for a given exercise load, a reduction of heart rate and systolic blood pressure as well as a drop in the PRP occurred at 8 weeks after administration. Therefore, bunazosin appears to improve cardiac function and exercise tolerance in the patients with DCM, at dosages which do not affect hemodynamics at rest.